Topic
Strait of Hormuz Research
Research surrounding the Strait of Hormuz highlights the significant impact of Iranian geopolitical tensions on global energy prices and bond yields. Analysts note a prevailing 'jaded cynicism' regarding potential US-Iran diplomatic resolutions, a factor that continues to keep oil prices elevated and contributes to widespread policy uncertainty. This geopolitical instability is driving inflationary concerns and recessionary risks, leading some institutions to view the current sell-off in government bonds as a strategic entry point for intermediate maturities. In the equity markets, there is a visible rotation toward early-cycle groups such as freight and airlines, which are breaking out of multi-year patterns despite vulnerabilities in other industrial sectors. Furthermore, the pass-through of supply chain costs remains a critical factor for investors as business investment falters in key global markets. Ultimately, the research suggests a tactical approach, balancing high-conviction style picks with quality bonds to hedge against the volatility inherent in the current geopolitical landscape.
4813 reports available
All reports
Page 201 of 201
Right Tail Risk in Consumer Discretionary
Goldman Sachs & Co. LLC · Apr 23, 2026
Equity Positioning and Key Levels
Goldman Sachs · Apr 13, 2026
Investment Strategy Quarterly
Raymond James · Apr 1, 2026
March and Q1 2026 Performance Review
Deutsche Bank · Apr 1, 2026
Markets and Macro
Goldman Sachs · Mar 29, 2026
Good Morning Mail
Goldman Sachs · Mar 25, 2026
Sentiment Positioning Late Cycle Tightening and Long Term Oil
Goldman Sachs International · Mar 14, 2026
Global Equities Call
Goldman Sachs · Mar 10, 2026
From Geopolitical Shocks To Structural Repricing
UBS · Mar 1, 2026
TMT Special Sales: Nvidia and Indra Beat, WPP Strategy, and Tech Conference Wrap
Goldman Sachs · Feb 26, 2026
When Tangible Wins
Goldman Sachs · Feb 20, 2026
Tactical Short: Expensive Defensives and Staples
Goldman Sachs & Co. LLC · Feb 20, 2026
Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals
William Blair · Jan 8, 2026